PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 6, 2026European Heart Journal0 citations

Oral PCSK9 Inhibitors for Lipid Management: A Meta-Analysis

Oral PCSK9 inhibitors as an emerging frontier in lipid management: a meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

VHV Q T HoNTN B TranNNNhan Nguyen

Discussion

Loading...

Member takes

Overview

Meta-analysis assesses efficacy and safety of oral PCSK9 inhibitors in lipid reduction, implying benefits for hypercholesterolemic patients.

Key Points

  • This research aims to evaluate the efficacy and safety of oral PCSK9 inhibitors in lowering lipid levels in hypercholesterolemic populations.
  • Conducted a systematic review and meta-analysis of randomized placebo-controlled trials.
  • Included three trials with a total of 638 patients.
  • Assessed mean differences and odds ratios for lipid levels and adverse events.
  • Patients receiving oral PCSK9 inhibitors experienced a significant reduction in LDL-C levels by 47.36%.
  • Triglycerides were reduced by 15.47% in the treatment group.
  • Apolipoprotein B levels decreased by 42.08% with oral PCSK9 inhibitors.

Cite This Study

Ho et al. (2025) studied this question.

synapsesocial.com/papers/698585758f7c464f23008db3https://doi.org/10.1093/eurheartj/ehaf784.3719
View Full Paper
Ask AI
Bookmark
Share